← All companies

AKTS

Aktis Oncology, Inc.

AKTS Nasdaq Pharmaceutical Preparations EDGAR ↗

$22.23

-0.77 -3.35%

Key statistics

from XBRL data in SEC filings

Market cap

$1.08B

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$372M

Total assets

$577M

Gross margin

—

52-week range

$14.72 – $34.19

Recent SEC filings

40 most recent

Annual, quarterly & current reports

10-Q Quarter ended 2026-03-31 May 11, 2026 8-K Results of operations (earnings release) May 11, 2026 8-K Director or officer change; Regulation FD disclosure Apr 16, 2026 8-K Results of operations (earnings release) Mar 30, 2026 10-K Fiscal year ended 2025-12-31 Mar 30, 2026 8-K Amended charter or bylaws Jan 12, 2026

Other filings

4 Jul 21, 2026 4 Jul 20, 2026 144 Jul 20, 2026 144 Jul 17, 2026 4 Jul 10, 2026 4 Jul 10, 2026 144 Jul 8, 2026 144 Jul 8, 2026 SCHEDULE 13G May 14, 2026 4 Apr 16, 2026 3 Apr 16, 2026 SCHEDULE 13D Jan 20, 2026 SCHEDULE 13D Jan 20, 2026 SCHEDULE 13D Jan 15, 2026 3 Jan 15, 2026 4 Jan 14, 2026 4 Jan 14, 2026 4 Jan 14, 2026 SCHEDULE 13D Jan 14, 2026 4 Jan 12, 2026 4 Jan 12, 2026 4 Jan 12, 2026 4 Jan 12, 2026 S-8 Jan 12, 2026 424B4 Jan 9, 2026 EFFECT Jan 8, 2026 3 Jan 8, 2026 3 Jan 8, 2026 3 Jan 8, 2026 3 Jan 8, 2026 3 Jan 8, 2026 3 Jan 8, 2026 3 Jan 8, 2026 3 Jan 8, 2026